View Older Stories View More Recent Stories
-
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Ad
-
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
-
Jaguar Health (JAGX) Appoints Susan Krizancic as National Sales Director at Jaguar family company Napo Pharmaceuticals
-
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
-
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
-
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
-
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
-
Jaguar Health (JAGX): Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome
-
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
-
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
-
Jaguar Health (JAGX): Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome
-
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
-
Jaguar Health (JAGX) Misses Q2 EPS by 404c
-
Jaguar Health Reports Second Quarter 2024 Financial Results
-
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and
-
Jaguar Health (JAGX) Issues Letter to Shareholders
-
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings an
-
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Il
-
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at America
-
Jaguar Health (JAGX): Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders
-
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
-
Jaguar Health (JAGX) Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
-
Jaguar Health (JAGX) phase 3 OnTarget trial did not meet its primary endpoint
-
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
-
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
-
Jaguar Health's (JAGX) Napo Receives New European & Australian Patents
-
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
-
Jaguar Health (JAGX) Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health (JAGX) Announces Approval of All Proposals at June 2024 Annual Meeting of Stockholders
-
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
-
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
